Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

INTRODUCTION: Glecaprevir/pibrentasvir (G/P) was approved on 26 September 2019 by the US Food and Drug Administration for 8-week duration in treatment-naïve (TN) hepatitis C virus (HCV)-infected patients with compensated cirrhosis (CC). Evidence from the EXPEDITION-8 study demonstrated that 8 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Flamm, Steven L., Kort, Jens, Marx, Steven E., Strezewski, John, Dylla, Douglas E., Bacon, Bruce, Curry, Michael P., Tsai, Naoky, Wick, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467488/
https://www.ncbi.nlm.nih.gov/pubmed/32279176
http://dx.doi.org/10.1007/s12325-020-01301-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467488/
https://www.ncbi.nlm.nih.gov/pubmed/32279176
http://dx.doi.org/10.1007/s12325-020-01301-5

Ejemplares similares